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Catheter Cardiovasc Interv 2008;72:424–5.Letters to the EditorIAL Trial Not Included
n a Review of Health Failure
anagement Programs
ecently, Clark et al. (1) reviewed what they considered all
vailable evidence on the effectiveness of disease management trialsethodological quality. They particularly emphasized the poor
uality of reports and design methods suggested by the Consoli-
ated Standards of Reporting Trials statement.
We fully agree with the importance of following such rules, not
nly during the reporting and writing phase but also during the
esign and implementation of clinical trials.
For this reason, we were surprised by the omission of the DIAL
Randomized Trial of Telephone Intervention in Chronic Heartlues fo
es in bi
D2R ailure) (2) from the investigators’ discussion. DIAL was the
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July 6, 2010:158–60argest and among the best designed and implemented trials in this
rea. The trial tested the effectiveness of a very applicable
elephone-based intervention, including more than 50 centers and
,500 patients, which reduced heart failure admissions by 30% (3).
n contrast, most trials in this area have included patients from
ingle centers, in academic environments, implementing complex
rograms, and in general they have not obtained similar results.
urthermore, DIAL was designed and reported according to
onsolidated Standards of Reporting Trials guidelines; its report
n the British Medical Journal fulfilled all aspects required by the
tatement, including a clearly defined intervention, a comparator or
ntervention in control group, measurement of events, a clearly
efined population, clear statements about the therapies and
ntensity of care in the control group, a flow chart of participants,
nd clearly stated objectives, end points, statistical analyses, and
esults.
DIAL was also an independent clinical trial and was conducted
n Argentina. Although we believe that these characteristics could
ake DIAL’s results less applicable for reviewers in developed
ountries, we would like to suggest that Clark et al. (1) discuss all
vailable evidence on the topic to both avoid bias and help
hysicians make appropriate decisions about the appropriateness
nd effectiveness of disease management programs in heart failure.
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eply
r. Ferrante and colleagues are correct to draw attention to the
erits of the DIAL (Randomized Trial of Telephone Intervention
n Chronic Heart Failure) because, unlike other trials, it was a large
nd comparatively well-described intervention delivered in a
iddle-income country. As such, DIAL is a welcome addition to
he evidence base.
However, we disagree that reports of DIAL meet the require-
ents of the modified Consolidated Standards of Reporting Trialstatement for nonpharmacological trials (1), because the original
nd companion reports (2) do not identify what usual care
onsisted of or how the care provided to the intervention group
as standardized or monitored. These new standards are impor-
ant, because they reflect principles of critical appraisal, and
etailed information is necessary for rigorous systematic review (3).
We agree with the authors that the results of program trials are
nconsistent. Current evidence does not adequately conceptualize
r describe programs (3). However, it is because of these weaknesses
hat further meta-analysis of programs is inappropriate. As such,
e did not seek to include “all” available evidence in our viewpoint
ut identified recent trials that did not find programs to be
eneficial.
We drew attention to the lack of understanding of why program
ffects vary (4). These variations can be dismissed or attributed to
iases or methodological weaknesses but may reflect actual differ-
nces in effects. Indeed, a very large recent trial (5) of another
redominantly telephone-based program for patients (n 30,000)
ith heart failure and diabetes reinforced the need to understand
rogram effects better. This independent evaluation found no
enefits from programs on hospitalization, mortality, patient
atisfaction, self-care, or mental and physical functioning. Costs
far exceeded” savings. These negative results must be considered
n the light of other positive findings, including those from DIAL.
In the face of these variations, proponents of different types of
rograms may continue to argue which type of program is “best,”
ut this reflects an overly simplistic approach to evidence-based
ealth services. Different types of programs are likely to be suitable
or different settings and populations with different resources.
eveloping a more nuanced and context-responsive evidence base
s now vital.
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